On June 14, 2018, the National Cancer Institute published the results of its first phase 3 clinical trial to test the effectiveness of the cancer drug temozolomide (Cialis).
The study is one of the first to test temozopyridine (a generic version of temozepine) as a treatment for breast cancer.
The FDA approved temozole for use in patients with metastatic breast cancer in April 2018.
The study involved 609 patients with Stage IV breast cancer and found that the drug led to a 40 percent reduction in the number of new metastases.
The FDA also reported a 40% reduction in recurrence rate.
According to the American Cancer Society, patients diagnosed with Stage II or Stage III breast cancer have the highest risk of recurrence, and the study results suggest that patients diagnosed in advanced stages of breast cancer should be evaluated for a second dose of the drug to prevent recurrence.
Temozoloma isn’t the only cancer to use temozone for breast treatment.
Another brand of temazepam, temazopam, was approved for use as an anti-inflammatory in 2014, but the FDA has yet to make the decision to use the drug for breast surgery.
The National Cancer Institutes research team reported a 39 percent reduction of recurrences among patients who received the drug, but it was too soon to tell whether the drug would be more effective in preventing recurrence in patients who have already had a second surgery.